BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 34039818)

  • 1. Conversion therapy and maintenance therapy for primary hepatocellular carcinoma.
    Zhou H; Song T
    Biosci Trends; 2021 Jul; 15(3):155-160. PubMed ID: 34039818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of postoperative adjuvant transcatheter arterial chemoembolization in hepatocellular carcinoma patients with microvascular invasion.
    Ye JZ; Chen JZ; Li ZH; Bai T; Chen J; Zhu SL; Li LQ; Wu FX
    World J Gastroenterol; 2017 Nov; 23(41):7415-7424. PubMed ID: 29151695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma.
    Kim HY; Kim JD; Bae SH; Park JY; Han KH; Woo HY; Choi JY; Yoon SK; Jang BK; Hwang JS; Kim SG; Kim YS; Seo YS; Yim HJ; Um SH;
    Korean J Hepatol; 2010 Dec; 16(4):355-61. PubMed ID: 21415578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma.
    Akateh C; Black SM; Conteh L; Miller ED; Noonan A; Elliott E; Pawlik TM; Tsung A; Cloyd JM
    World J Gastroenterol; 2019 Jul; 25(28):3704-3721. PubMed ID: 31391767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status.
    Kodama K; Kawaoka T; Aikata H; Uchikawa S; Inagaki Y; Hatooka M; Morio K; Nakahara T; Murakami E; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Masaki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Chayama K
    J Gastroenterol Hepatol; 2018 Oct; 33(10):1780-1786. PubMed ID: 29645345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study.
    He MK; Le Y; Li QJ; Yu ZS; Li SH; Wei W; Guo RP; Shi M
    Chin J Cancer; 2017 Oct; 36(1):83. PubMed ID: 29061175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic arterial infusion chemotherapy vs transcatheter arterial embolization for patients with huge unresectable hepatocellular carcinoma.
    Tsai WL; Sun WC; Chen WC; Chiang CL; Lin HS; Liang HL; Cheng JS
    Medicine (Baltimore); 2020 Aug; 99(32):e21489. PubMed ID: 32769883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemoembolization alone vs combined chemoembolization and hepatic arterial infusion chemotherapy in inoperable hepatocellular carcinoma patients.
    Gao S; Zhang PJ; Guo JH; Chen H; Xu HF; Liu P; Yang RJ; Zhu X
    World J Gastroenterol; 2015 Sep; 21(36):10443-52. PubMed ID: 26420971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical efficacy of postoperative adjuvant transcatheter arterial chemoembolization on hepatocellular carcinoma.
    Liu C; Sun L; Xu J; Zhao Y
    World J Surg Oncol; 2016 Apr; 14():100. PubMed ID: 27038790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Options and survival benefits of conversion therapy for unresectable hepatocellular carcinoma.
    She WH; Cheung TT
    World J Gastroenterol; 2024 May; 30(18):2479-2481. PubMed ID: 38764761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absence of Benefit of Transcatheter Arterial Chemoembolization (TACE) in Patients with Resectable Solitary Hepatocellular Carcinoma.
    Ha TY; Hwang S; Lee YJ; Kim KH; Ko GY; Ii Gwon D; Ahn CS; Moon DB; Song GW; Jung DH; Lee HC; Lim YS; Kim KM; Shim JH; Choi JH; Lee SG
    World J Surg; 2016 May; 40(5):1200-10. PubMed ID: 26666422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcomes of hepatocellular carcinoma that underwent chemoembolization for bridging or downstaging.
    Affonso BB; Galastri FL; da Motta Leal Filho JM; Nasser F; Falsarella PM; Cavalcante RN; de Almeida MD; Felga GEG; Valle LGM; Wolosker N
    World J Gastroenterol; 2019 Oct; 25(37):5687-5701. PubMed ID: 31602168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylactic hepatic artery infusion chemotherapy improved survival after curative resection in patients with hepatocellular carcinoma.
    Huang SX; Wu YL; Tang CW; Feng WM; Xu YQ; Bao Y; Zheng YY
    Hepatogastroenterology; 2015; 62(137):122-5. PubMed ID: 25911881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized controlled trial of hepatectomy with adjuvant transcatheter arterial chemoembolization versus hepatectomy alone for Stage III A hepatocellular carcinoma.
    Zhong C; Guo RP; Li JQ; Shi M; Wei W; Chen MS; Zhang YQ
    J Cancer Res Clin Oncol; 2009 Oct; 135(10):1437-45. PubMed ID: 19408012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization.
    Hatooka M; Kawaoka T; Aikata H; Morio K; Kobayashi T; Hiramatsu A; Imamura M; Kawakami Y; Murakami E; Waki K; Honda Y; Mori N; Takaki S; Tsuji K; Kohno H; Kohno H; Moriya T; Nonaka M; Hyogo H; Aisaka Y; Chayama K
    Anticancer Res; 2016 Jul; 36(7):3523-9. PubMed ID: 27354618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic predictors for patients with hepatocellular carcinoma receiving adjuvant transcatheter arterial chemoembolization.
    Gu J; Zhang X; Cui R; Zhang J; Wang Z; Jia Y; Miao R; Dong Y; Ma X; Fan H; Wang H; Ren L; Li Y; Niu W; Zhang J; Qu K; Liu C
    Eur J Gastroenterol Hepatol; 2019 Jul; 31(7):836-844. PubMed ID: 30614882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distribution of tumor stage and initial treatment modality in patients with primary hepatocellular carcinoma.
    Xiang X; Zhong JH; Wang YY; You XM; Ma L; Xiang BD; Li LQ
    Clin Transl Oncol; 2017 Jul; 19(7):891-897. PubMed ID: 28160206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential transarterial chemoembolization and portal vein embolization before resection is a valid oncological strategy for unilobar hepatocellular carcinoma regardless of the tumor burden.
    Ronot M; Cauchy F; Gregoli B; Breguet R; Allaham W; Paradis V; Soubrane O; Vilgrain V
    HPB (Oxford); 2016 Aug; 18(8):684-90. PubMed ID: 27485063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcatheter arterial chemoembolization alone or combined with ablation for recurrent intermediate-stage hepatocellular carcinoma: a propensity score matching study.
    Wang C; Liao Y; Qiu J; Yuan Y; Zhang Y; Li K; Zou R; Wang Y; Zuo D; He W; Zheng Y; Li B; Yuan Y
    J Cancer Res Clin Oncol; 2020 Oct; 146(10):2669-2680. PubMed ID: 32449005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study of local three-dimensional conformal radiotherapy combined with transcatheter arterial chemoembolization for patients with stage III hepatocellular carcinoma.
    Li B; Yu J; Wang L; Li C; Zhou T; Zhai L; Xing L
    Am J Clin Oncol; 2003 Aug; 26(4):e92-9. PubMed ID: 12902905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.